Elecoglipron and the SOLSTICE Trial: What It Means for the Pill Market
Key Takeaways
- Elecoglipron is a second oral small-molecule GLP-1 — from Pfizer, not Lilly
- The SOLSTICE Phase 2b trial showed up to ~9% weight loss at 32 weeks at the highest dose
- That's less than orforglipron or oral semaglutide, but it's still early-stage data
- Pfizer entered the GLP-1 race late — Phase 3 results and FDA filing are likely 2027+
- The competitive significance: it proves the small-molecule oral GLP-1 approach isn't a one-company story
Pfizer's elecoglipron (formerly danuglipron, then reformulated as a once-daily version) is the second oral small-molecule GLP-1 agonist to produce meaningful clinical data. The SOLSTICE trial results landed in 2025–2026, and while they're not as headline-grabbing as orforglipron's ATTAIN data, they matter for the trajectory of the oral GLP-1 market.
SOLSTICE Trial Results
The SOLSTICE trial was a Phase 2b dose-ranging study in adults with obesity or overweight with at least one weight-related comorbidity. Key findings:
| Dose | Weight Loss (32 weeks) | Discontinuation Rate |
|---|---|---|
| Low dose | ~3–4% | Moderate |
| Mid dose | ~6–7% | Moderate |
| High dose | ~8–9% | Higher (GI side effects) |
| Placebo | ~1.5% | Low |
The ~9% weight loss at 32 weeks is clinically meaningful but notably below what orforglipron (Foundayo) and oral semaglutide (Wegovy pill) have demonstrated. A few important caveats:
- Shorter duration: SOLSTICE ran 32 weeks; ATTAIN and OASIS ran 40–72 weeks. Weight loss with GLP-1s typically continues beyond 32 weeks.
- Dose-finding phase: Phase 2b is about finding the right dose, not proving maximum efficacy. Phase 3 will test optimized doses over longer periods.
- GI tolerability: Higher doses showed more nausea and vomiting, which contributed to dropout rates. Formulation adjustments may improve this.
What This Means for the Pill Market
Elecoglipron's significance isn't that it's better than what's already available — it's that it proves the oral small-molecule GLP-1 approach works for multiple companies. Competition drives prices down and accelerates innovation. Even if Pfizer's product ends up third-to-market, its existence pressures Lilly and Novo Nordisk on pricing and access.
Timeline
Phase 3 trials are expected to begin or are underway. At typical development timelines, the earliest an FDA filing could happen is late 2027, with potential approval in 2028. That's a long way off — by then, oral Wegovy and Foundayo will be well-established, and oral tirzepatide may also be on the market.
What's Available Now
If you're interested in oral GLP-1 treatment today, you don't need to wait for elecoglipron. FDA-approved options include oral Wegovy (semaglutide) and Foundayo (orforglipron), plus compounded oral alternatives at lower price points.
MadeMed
Oral SemaglutideCompounded oral semaglutide in tablet form. Quarterly plan brings cost to $89/month; monthly refill is $119/month.
MadeMed
Oral TirzepatideCompounded oral tirzepatide tablets. Quarterly plan brings cost to $89/month; monthly refill is $119/month.
Elecoglipron and the SOLSTICE trial prove that oral small-molecule GLP-1s are a real drug class, not a single-product fluke. But the data so far shows it's behind orforglipron and oral semaglutide on efficacy, and it's years from market. Watch it as a competitive signal — the more companies building oral GLP-1 pills, the better the prices and options will be for everyone.
Clinical trial data referenced from publicly available SOLSTICE trial results. Consult your healthcare provider about currently available treatment options.